Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideALNYAlnylam Pharmaceuticals
FinDog View：Neutral
| Metric | ALNY | AMGN |
|---|
| Close | 227.02 | 417.57 |
| Market Cap | $31.1B | $224B |
| 1M | −8.71% | +10.66% |
| P/E (TTM) | 38.5 | 25.7 |
| Forward P/E | 28.0 | 17.1 |
| P/E 5-Yr Percentile | — | 50 |
| P/S | 6.5 | 5.9 |
| P/B | 23.0 | 19.2 |
| Dividend Yield | — | 3.21% |
| Latest Quarter Revenue | $1.3B | $10.1B |
| Revenue YoY | +66.9% | +9.5% |
| Gross Margin | 76.9% | 72.0% |
| Latest Quarter EPS | 1.21 | 4.37 |
| Avg Post-Earnings Move | ±1.7% | ±5.2% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | — | 2.36% |
| 90-Day Net Insider Buying | −$0.40M | −$4.1M |
ALNY · Revenue, Last 8 Quarters ($B)
AMGN · Revenue, Last 8 Quarters ($B)
